Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines

Keisuke Aoe, Katsuyuki Kiura, Hiroshi Ueoka, Masahiro Tabata, Masakazu Chikamori, Hiroyuki Kohara, Mine Harada, Mitsune Tanimoto

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Many clinical studies have reported that irinotecan has reproducible antitumor activity against lung cancer. Both cisplatin and SN-38 are key drugs in the treatment of lung cancer, and their combination is one of the most promising regimens available. Using lung cancer cell lines, ABC-1 and SBC-3, we examined the cytotoxic effect of the schedule, as well as the effect of cisplatin on topoisomerase I activity. Cytotoxicity was determined by MTT assay. ABC-1 or SBC-3 cells were incubated with or without various concentrations of both drugs in 96-well microplates for 72 or 96 hours in a humidified 5% CO 2 atmosphere at 37°C. Synergism was evaluated by median-effect plot analysis and a combination index isobologram method by Chou and Talalay. After ABC-1 or SBC-3 cells had been exposed to 10 μM cisplatin for one hour, topoisomerase I activities were determined by supercoiled-DNA relaxation assay. Synergism was observed in ABC-1 and SBC-3 cells when cisplatin was given first, followed by SN-38 (7-ethyl-10-hydroxycamptothecin) and cisplatin. Topoisomerase I activity decreased at 1-2 hours after exposure to cisplatin and recovered gradually after 4-5 hours of cisplatin exposure in both ABC-1 and SBC-3 cells. Accordingly, pretreatment with cisplatin will have an impact on the sensitivity to SN-38.

Original languageEnglish
Pages (from-to)3893-3897
Number of pages5
JournalAnticancer Research
Volume24
Issue number6
Publication statusPublished - Nov 2004

Fingerprint

irinotecan
Type I DNA Topoisomerase
Cisplatin
Lung Neoplasms
Down-Regulation
Cell Line
Superhelical DNA
Carbon Monoxide
Atmosphere
Pharmaceutical Preparations
Appointments and Schedules

Keywords

  • Cisplatin
  • Irinotecan
  • Lung cancer
  • Topoisomerase I

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Aoe, K., Kiura, K., Ueoka, H., Tabata, M., Chikamori, M., Kohara, H., ... Tanimoto, M. (2004). Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines. Anticancer Research, 24(6), 3893-3897.

Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines. / Aoe, Keisuke; Kiura, Katsuyuki; Ueoka, Hiroshi; Tabata, Masahiro; Chikamori, Masakazu; Kohara, Hiroyuki; Harada, Mine; Tanimoto, Mitsune.

In: Anticancer Research, Vol. 24, No. 6, 11.2004, p. 3893-3897.

Research output: Contribution to journalArticle

Aoe, K, Kiura, K, Ueoka, H, Tabata, M, Chikamori, M, Kohara, H, Harada, M & Tanimoto, M 2004, 'Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines', Anticancer Research, vol. 24, no. 6, pp. 3893-3897.
Aoe, Keisuke ; Kiura, Katsuyuki ; Ueoka, Hiroshi ; Tabata, Masahiro ; Chikamori, Masakazu ; Kohara, Hiroyuki ; Harada, Mine ; Tanimoto, Mitsune. / Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines. In: Anticancer Research. 2004 ; Vol. 24, No. 6. pp. 3893-3897.
@article{690581570865430ea4aef56057c4d177,
title = "Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines",
abstract = "Many clinical studies have reported that irinotecan has reproducible antitumor activity against lung cancer. Both cisplatin and SN-38 are key drugs in the treatment of lung cancer, and their combination is one of the most promising regimens available. Using lung cancer cell lines, ABC-1 and SBC-3, we examined the cytotoxic effect of the schedule, as well as the effect of cisplatin on topoisomerase I activity. Cytotoxicity was determined by MTT assay. ABC-1 or SBC-3 cells were incubated with or without various concentrations of both drugs in 96-well microplates for 72 or 96 hours in a humidified 5{\%} CO 2 atmosphere at 37°C. Synergism was evaluated by median-effect plot analysis and a combination index isobologram method by Chou and Talalay. After ABC-1 or SBC-3 cells had been exposed to 10 μM cisplatin for one hour, topoisomerase I activities were determined by supercoiled-DNA relaxation assay. Synergism was observed in ABC-1 and SBC-3 cells when cisplatin was given first, followed by SN-38 (7-ethyl-10-hydroxycamptothecin) and cisplatin. Topoisomerase I activity decreased at 1-2 hours after exposure to cisplatin and recovered gradually after 4-5 hours of cisplatin exposure in both ABC-1 and SBC-3 cells. Accordingly, pretreatment with cisplatin will have an impact on the sensitivity to SN-38.",
keywords = "Cisplatin, Irinotecan, Lung cancer, Topoisomerase I",
author = "Keisuke Aoe and Katsuyuki Kiura and Hiroshi Ueoka and Masahiro Tabata and Masakazu Chikamori and Hiroyuki Kohara and Mine Harada and Mitsune Tanimoto",
year = "2004",
month = "11",
language = "English",
volume = "24",
pages = "3893--3897",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines

AU - Aoe, Keisuke

AU - Kiura, Katsuyuki

AU - Ueoka, Hiroshi

AU - Tabata, Masahiro

AU - Chikamori, Masakazu

AU - Kohara, Hiroyuki

AU - Harada, Mine

AU - Tanimoto, Mitsune

PY - 2004/11

Y1 - 2004/11

N2 - Many clinical studies have reported that irinotecan has reproducible antitumor activity against lung cancer. Both cisplatin and SN-38 are key drugs in the treatment of lung cancer, and their combination is one of the most promising regimens available. Using lung cancer cell lines, ABC-1 and SBC-3, we examined the cytotoxic effect of the schedule, as well as the effect of cisplatin on topoisomerase I activity. Cytotoxicity was determined by MTT assay. ABC-1 or SBC-3 cells were incubated with or without various concentrations of both drugs in 96-well microplates for 72 or 96 hours in a humidified 5% CO 2 atmosphere at 37°C. Synergism was evaluated by median-effect plot analysis and a combination index isobologram method by Chou and Talalay. After ABC-1 or SBC-3 cells had been exposed to 10 μM cisplatin for one hour, topoisomerase I activities were determined by supercoiled-DNA relaxation assay. Synergism was observed in ABC-1 and SBC-3 cells when cisplatin was given first, followed by SN-38 (7-ethyl-10-hydroxycamptothecin) and cisplatin. Topoisomerase I activity decreased at 1-2 hours after exposure to cisplatin and recovered gradually after 4-5 hours of cisplatin exposure in both ABC-1 and SBC-3 cells. Accordingly, pretreatment with cisplatin will have an impact on the sensitivity to SN-38.

AB - Many clinical studies have reported that irinotecan has reproducible antitumor activity against lung cancer. Both cisplatin and SN-38 are key drugs in the treatment of lung cancer, and their combination is one of the most promising regimens available. Using lung cancer cell lines, ABC-1 and SBC-3, we examined the cytotoxic effect of the schedule, as well as the effect of cisplatin on topoisomerase I activity. Cytotoxicity was determined by MTT assay. ABC-1 or SBC-3 cells were incubated with or without various concentrations of both drugs in 96-well microplates for 72 or 96 hours in a humidified 5% CO 2 atmosphere at 37°C. Synergism was evaluated by median-effect plot analysis and a combination index isobologram method by Chou and Talalay. After ABC-1 or SBC-3 cells had been exposed to 10 μM cisplatin for one hour, topoisomerase I activities were determined by supercoiled-DNA relaxation assay. Synergism was observed in ABC-1 and SBC-3 cells when cisplatin was given first, followed by SN-38 (7-ethyl-10-hydroxycamptothecin) and cisplatin. Topoisomerase I activity decreased at 1-2 hours after exposure to cisplatin and recovered gradually after 4-5 hours of cisplatin exposure in both ABC-1 and SBC-3 cells. Accordingly, pretreatment with cisplatin will have an impact on the sensitivity to SN-38.

KW - Cisplatin

KW - Irinotecan

KW - Lung cancer

KW - Topoisomerase I

UR - http://www.scopus.com/inward/record.url?scp=14944348037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14944348037&partnerID=8YFLogxK

M3 - Article

C2 - 15736428

AN - SCOPUS:14944348037

VL - 24

SP - 3893

EP - 3897

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -